胆管癌的免疫治疗：值得重新审视。
Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look.
机构信息
Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.
出版信息
Cancer Control. 2020 Jul-Aug;27(3):1073274820948047. doi: 10.1177/1073274820948047.
Abstract
Although immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape of several malignancies, the role of immunotherapy in biliary tract cancer (BTC) is currently under investigation and ICIs are still looking for their niche in this setting. In this Editorial, we discuss recently published data regarding ICIs in BTC, with a particular focus in terms of selection of patients and biomarker-driven trials.
摘要
尽管免疫检查点抑制剂 (ICIs) 已经彻底改变了几种恶性肿瘤的治疗格局，但免疫疗法在胆管癌 (BTC) 中的作用目前仍在研究中，ICI 在这种情况下仍在寻找其定位。在这篇社论中，我们讨论了最近发表的关于 BTC 中 ICI 的数据，特别关注患者选择和生物标志物驱动的试验。
相似文献
1
Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look.胆管癌的免疫治疗：值得重新审视。
Cancer Control. 2020 Jul-Aug;27(3):1073274820948047. doi: 10.1177/1073274820948047.
2
Recent advances of immunotherapy for biliary tract cancer.免疫治疗在胆管癌中的最新进展。
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):527-536. doi: 10.1080/17474124.2021.1853527. Epub 2021 Jan 8.
3
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer.度伐利尤单抗：一种研究性抗 PD-L1 抗体，用于治疗胆管癌。
Expert Opin Investig Drugs. 2021 Apr;30(4):343-350. doi: 10.1080/13543784.2021.1897102. Epub 2021 Mar 9.
4
Nivolumab: an investigational agent for the treatment of biliary tract cancer.纳武利尤单抗：一种用于治疗胆道癌的研究性药物。
Expert Opin Investig Drugs. 2021 Apr;30(4):325-332. doi: 10.1080/13543784.2021.1863946. Epub 2020 Dec 23.
5
Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.抗 PD-1 抗体卡瑞利珠单抗单药治疗胆道系统肿瘤患者的经验及文献复习。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820979703. doi: 10.1177/1533033820979703.
6
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.PD-L1、肿瘤突变负荷、微卫星不稳定性及其他胆管癌中免疫检查点抑制剂反应的预测指标
Cancers (Basel). 2021 Feb 1;13(3):558. doi: 10.3390/cancers13030558.
7
Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.免疫检查点抑制剂在结直肠癌治疗中的现状与展望。
Jpn J Clin Oncol. 2021 Jan 1;51(1):10-19. doi: 10.1093/jjco/hyaa200.
8
Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma).胆道癌（胆管癌）中的免疫检查点抑制剂疗法
Chin Clin Oncol. 2020 Feb;9(1):2. doi: 10.21037/cco.2019.12.10. Epub 2020 Jan 7.
9
Current and emerging immunotherapeutic approaches for biliary tract cancers.当前和新兴的胆管癌免疫治疗方法。
Hepatobiliary Pancreat Dis Int. 2022 Oct;21(5):440-449. doi: 10.1016/j.hbpd.2022.08.015. Epub 2022 Sep 7.
10
Advances in immunotherapy for biliary tract cancers.胆管癌免疫治疗的进展
Chin Med J (Engl). 2024 Mar 5;137(5):524-532. doi: 10.1097/CM9.0000000000002759. Epub 2023 Aug 29.
引用本文的文献
1
Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers.多组学分析揭示了晚期不可切除胆管癌化学免疫治疗疗效和预后的预测生物标志物。
BMC Med. 2025 Jul 22;23(1):435. doi: 10.1186/s12916-025-04263-z.
2
Feasibility of machine learning-based modeling and prediction to assess osteosarcoma outcomes.基于机器学习的建模和预测评估骨肉瘤预后的可行性。
Sci Rep. 2025 May 19;15(1):17386. doi: 10.1038/s41598-025-00179-z.
3
Camrelizumab in combination with chemotherapy and targeted therapy improves the prognosis in patients with advanced biliary tract cancer: a single-center retrospective clinical study.卡瑞利珠单抗联合化疗和靶向治疗改善晚期胆管癌患者预后：一项单中心回顾性临床研究
J Gastrointest Oncol. 2025 Apr 30;16(2):660-670. doi: 10.21037/jgo-2025-184. Epub 2025 Apr 27.
4
Comparative efficacy of targeted therapy, chemotherapy and their combination for advanced cholangiocarcinoma: a systematic review and network meta-analysis.靶向治疗、化疗及其联合治疗晚期胆管癌的疗效比较：一项系统评价和网状Meta分析
PeerJ. 2025 May 14;13:e19386. doi: 10.7717/peerj.19386. eCollection 2025.
5
Preoperative glasgow prognostic score was an effective prognostic indicator in patients with biliary tract cancer.术前格拉斯哥预后评分是胆道癌患者有效的预后指标。
Front Immunol. 2025 Apr 8;16:1560944. doi: 10.3389/fimmu.2025.1560944. eCollection 2025.
6
Alterations in genomic features and the tumour immune microenvironment predict immunotherapy outcomes in advanced biliary tract cancer patients.基因组特征和肿瘤免疫微环境的改变可预测晚期胆管癌患者的免疫治疗结果。
Br J Cancer. 2025 Apr 10. doi: 10.1038/s41416-025-03011-7.
7
Comparison of monotherapy and combination therapy for older patients with advanced biliary tract cancer: a retrospective study.老年晚期胆管癌患者单药治疗与联合治疗的比较：一项回顾性研究。
BMC Cancer. 2025 Apr 9;25(1):653. doi: 10.1186/s12885-025-14014-1.
8
Role of cancer stem cell heterogeneity in intrahepatic cholangiocarcinoma.癌症干细胞异质性在肝内胆管癌中的作用
Transl Cancer Res. 2025 Feb 28;14(2):1265-1281. doi: 10.21037/tcr-24-1286. Epub 2025 Feb 26.
9
Immunotherapy-induced microsatellite instability status shift in recurrent perihilar cholangiocarcinoma: A case report.免疫治疗引起的复发性肝门周围胆管癌微卫星不稳定性状态改变：一例报告
Hum Vaccin Immunother. 2025 Dec;21(1):2471226. doi: 10.1080/21645515.2025.2471226. Epub 2025 Feb 25.
10
Comparing Immunotherapy Versus Chemotherapy Alone as Second-Line Therapy for Malignant Tumors of the Biliary Tract: A Retrospective Study.比较免疫疗法与单纯化疗作为胆道恶性肿瘤二线治疗的疗效：一项回顾性研究。
Clin Med Insights Oncol. 2025 Feb 16;19:11795549251317012. doi: 10.1177/11795549251317012. eCollection 2025.
本文引用的文献
1
Molecular profile of BRCA-mutated biliary tract cancers.BRCA 突变型胆道癌的分子特征。
ESMO Open. 2020 Jun;5(3):e000682. doi: 10.1136/esmoopen-2020-000682.
2
Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.晚期胆道癌的二线治疗：今天和明天。
Anticancer Res. 2020 Jun;40(6):3013-3030. doi: 10.21873/anticanres.14282.
3
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.纳武利尤单抗治疗晚期难治性胆道癌患者的 2 期多中心研究。
JAMA Oncol. 2020 Jun 1;6(6):888-894. doi: 10.1001/jamaoncol.2020.0930.
4
HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.HLA 校正的肿瘤突变负担和同源重组缺陷预测晚期非小细胞肺癌患者对 PD-(L)1 阻断的反应。
Ann Oncol. 2020 Jul;31(7):902-911. doi: 10.1016/j.annonc.2020.04.004. Epub 2020 Apr 19.
5
Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.分子靶向治疗：在胆管癌中准备“黄金时间”。
J Hepatol. 2020 Jul;73(1):170-185. doi: 10.1016/j.jhep.2020.03.007. Epub 2020 Mar 12.
6
Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis.晚期或转移性胃癌的三线及后线治疗：系统评价和荟萃分析。
Future Oncol. 2020 Jan;16(2):4409-4418. doi: 10.2217/fon-2019-0429. Epub 2019 Dec 3.
7
Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.多种癌症类型中同源重组相关基因突变的患病率。
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00286. Epub 2018 Jul 23.
8
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.美国食品药品监督管理局首次批准与癌症部位无关——当生物标志物确定适应症时。
N Engl J Med. 2017 Oct 12;377(15):1409-1412. doi: 10.1056/NEJMp1709968.
9
Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.肝内胆管癌的全身治疗和辅助治疗
Cancer Control. 2017 Jul-Sep;24(3):1073274817729241. doi: 10.1177/1073274817729241.
10
Targeting cholangiocarcinoma.胆管癌靶向治疗。
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1454-1460. doi: 10.1016/j.bbadis.2017.08.027. Epub 2017 Aug 24.
Zotero 插件